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Abstract
Background: A wide spectrum of disease severity has been described for Human African Trypanosomiasis (HAT) due to
Trypanosoma brucei rhodesiense (T.b. rhodesiense), ranging from chronic disease patterns in southern countries of East Africa
to an increase in virulence towards the north. However, only limited data on the clinical presentation of T.b. rhodesiense HAT
is available. From 2006-2009 we conducted the first clinical trial program (IMPAMEL III) in T.b. rhodesiense endemic areas of
Tanzania and Uganda in accordance with international standards (ICH-GCP). The primary and secondary outcome measures
were safety and efficacy of an abridged melarsoprol schedule for treatment of second stage disease. Based on diagnostic
findings and clinical examinations at baseline we describe the clinical presentation of T.b. rhodesiense HAT in second stage
patients from two distinct geographical settings in East Africa.
Methodology/Principal Findings: 138 second stage patients from Tanzania and Uganda were enrolled. Blood samples were
collected for diagnosis and molecular identification of the infective trypanosomes, and T.b. rhodesiense infection was
confirmed in all trial subjects. Significant differences in diagnostic parameters and clinical signs and symptoms were
observed: the median white blood cell (WBC) count in the cerebrospinal fluid (CSF) was significantly higher in Tanzania
(134cells/mm
3) than in Uganda (20cells/mm
3;p ,0.0001). Unspecific signs of infection were more commonly seen in
Uganda, whereas neurological signs and symptoms specific for HAT dominated the clinical presentation of the disease in
Tanzania. Co-infections with malaria and HIV did not influence the clinical presentation nor treatment outcomes in the
Tanzanian study population.
Conclusions/Significance: We describe a different clinical presentation of second stage T.b. rhodesiense HAT in two distinct
geographical settings in East Africa. In the ongoing absence of sensitive diagnostic tools and safe drugs to diagnose and
treat second stage T.b. rhodesiense HAT an early identification of the disease is essential. A detailed understanding of the
clinical presentation of T.b. rhodesiense HAT among health personnel and affected communities is vital, and awareness of
regional characteristics, as well as implications of co-infections, can support decision making and differential diagnosis.
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Introduction
Human African Trypanosomiasis (HAT), also known as sleeping
sickness, is caused by the protozoan parasites T.b. gambiense (West
and Central Africa) and T.b. rhodesiense (East and South Africa). The
disease is transmitted by tsetse flies (Glossina ssp.) predominantly in
the rural areas of most of sub Saharan Africa. 60 Million people live
at risk of infection, but less than 10% are under adequate
surveillance [1], reflecting its neglected status. Sleeping sickness
caused by either subspecies presents in two disease stages defined as
the first, or haemo-lymphatic stage and the second, meningo-
encephalitic stage. Diagnosis of HAT is made in blood, lymph and
the cerebrospinal fluid (CSF). The second stage of the disease is
indicated bythepresence oftrypanosomesand/oranelevatedwhite
blood cell (WBC) count ($5WBC/mm
3) in the CSF. The disease
stage and the causative species of infection direct the choice of
treatment. T.b. gambiense infections are treated with pentamidine in
the first stage and eflornithine, a combination of eflornithine and
nifurtimox, or melarsoprol in the second stage [2–4]. T.b. rhodesiense
first and second stage infections are treated with suramin and
melarsoprol respectively [2]. In the field, the trypanosome
subspecies is entirely determined by the geographical location of
the patient as the distinction of T.b. gambiense and T.b. rhodesiense is
only possible in well equipped laboratories through PCR analysis.
The detection of the human serum resistance-associated (SRA) gene
unequivocally identifies T.b. rhodesiense trypanosomes [5,6]. In
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present, a potential geographical overlap of the two endemic areas
has become likely [7]. This would hamper determination of
infective trypanosomes under field conditions and therefore also
the identification of the correct treatment.
For first stage infections there are no specific clinical signs and
symptoms in both forms of the disease; fever, headache and loss of
appetite are common. In T.b. rhodesiense the presence of a chancre
at the site of the infective bite may be indicative for a trypanosome
infection [8]. Second stage infections show disease-characteristic
neuro-psychiatric signs and symptoms: severe endocrinological
and mental disturbances and severe motor problems are the main
signs [9]. While often considered together, Gambiense and
Rhodesiense HAT are clinically and epidemiologically different
diseases [10]. T.b. gambiense HAT is a chronic disease, whereas T.b.
rhodesiense is characterized by an acute disease progression. If left
untreated, both forms of HAT are fatal. The mean time to reach
the second stage has been estimated at over one year for T.b.
gambiense [11] but only 3 weeks for T.b. rhodesiense HAT [12].
Correspondingly, average times from infection to death are almost
3 years and 6 to 12 months, respectively [11,12].
A diversity of forms of clinical progression from asymptomatic to
acute have been reported for T.b. gambiense infections [13–15]. This
seems to be even more pronounced for T.b. rhodesiense infections; a
wide spectrum of disease severity ranging from a chronic disease
pattern in southern countries of East Africa with existing reports of
asymptomatic carriers [16] to an increase in virulence towards the
north had been described [17]. Even though those differences were
already described more than 60 years ago [18] the first comparative
study was carried out in 2004: on the basis of the SRA gene
polymorphism, trypanosomes isolates from Uganda (acute profile)
and Malawi (chronic profile) confirmed to be of different genotypes.
However, clinical characteristics of the study groups were limited
the presence of a chancre and the self-reported duration of illness
[19]. Another hypothesis postulates that the differences in disease
severity could be attributed to differences in genetic resistance to
trypanosomiasis among host populations [18].
From the estimated 509000 to 70900 cases per year [20], over
97% are T.b. gambiense cases and only a few thousand are due to
T.b. rhodesiense [1]. Therefore, most literature concentrates on T.b.
gambiense HAT. Its clinical picture and related cardiac and
endocrinological disorders have been extensively described [21–
28]. On the other hand, literature on the clinical aspects of T.b.
rhodesiense HAT is scarce. We identified four studies (see table 1)
describing its clinical presentation. Only one study in 60 patients
infected with T.b. rhodesiense was designed prospectively and used a
standardized questionnaire [29].
In this paper we describe the clinical presentation of second
stage T.b. rhodesiense HAT in 138 patients from two distinct
geographical settings in East Africa. We compare our findings to
the existing literature and discuss factors that could explain the
differences observed.
Materials and Methods
Study sites
The Kaliua Health Centre (KHC), a 50-bed missionary hospital
in Tanzania (Urambo District) and the Lwala Hospital, a
designated 100- bed district hospital in Uganda (Kaberamaido
District) participated in the IMPAMEL III program (improved
application of melarsoprol).
Study design and data collection
A proof-of-concept trial (n=60) followed by a utilization study
(n=78) to assess the safety and efficacy of the abridged, 10-day
melarsoprol schedule for the treatment of second stage HAT
[30,31] in T.b. rhodesiense patients.
Eligible for enrolment were second stage patients with a
minimum age of 6 years and confirmed second stage HAT.
Patients with first stage infections, pregnant women and moribund
or unconscious patients were excluded. Patients were passively
enrolled at the study sites.
Diagnosis of HAT was made in blood and in CSF. Blood was
examined using microscopy and/or the haematocrit centrifugation
technique [32]. If trypanosomes were present, a lumbar puncture
was performed for disease staging. Analysis of the CSF was done
by direct microscopy and/or single modified centrifugation
technique and white blood cell (WBC) count using counting
chambers. Second stage infections were confirmed by the presence
of trypanosomes and/or $5 WBC/mm
3 in the CSF. The
standard assessment of co-infections included malaria, filariasis
and voluntary testing for HIV/AIDS.
The local Principal Investigators filled individual case report
forms (CRFs). Data used for describing the clinical presentation of
the disease were patient demographics, diagnostic findings, self
reported duration of illness and clinical signs and symptoms on
admission graded by scale of severity (grade 0, 1, 2).
Ethics statement
Each participant gave written informed consent. For the
participation of children and adolescents (below 18 years) the
parents, the legal representative or the guardian gave written
informed consent. Ethical clearances were obtained from the
Ethics Committees in Tanzania (National Institute for Medical
Research), Uganda (Ministry of Health) and Switzerland (Ethics
Committee of both cantons of Basel). Before first patient
enrolment, the IMPAMEL III program was registered in the database
of Current Controlled Trials (ISRCTN40537886).
Data management and statistical analysis
All data were double entered and verified using Epi Data 3.1
software (www.epidata.dk) and analysis was accomplished with the
statistical software package STATA Version IC10.0 (STATA,
StataCorp, USA). The statistical analysis was performed compar-
Author Summary
Sleeping sickness, or Human African Trypanosomiasis
(HAT), caused by Trypanosoma brucei rhodesiense is one
of the most neglected tropical diseases. It affects mainly
rural, poor East African populations and has very high
socio-economic impacts. T.b. rhodesiense HAT is an acute
disease; patients quickly progress from the first stage,
where trypanosomes are detectable in blood and lymph,
to the second stage, where parasites penetrate the central
nervous system. If left untreated, T.b. rhodesiense HAT is
fatal. Disease control is hampered by the absence of
sensitive diagnostic tools and safe drugs. Second stage
patients can only be treated with melarsoprol, a highly
toxic, arsenical drug. It is more difficult to treat patients
successfully at advanced stages of the disease, and late
onset of treatment should be avoided. Yet, most patients
are treated for other conditions prior to HAT diagnosis.
Therefore, it is important that health personnel in T.b.
rhodesiense endemic regions have a detailed understand-
ing of the clinical presentation of the disease and consider
regional characteristics of T.b. rhodesiense HAT for decision
making and differential diagnosis.
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www.plosntds.org 2 March 2011 | Volume 5 | Issue 3 | e968Table 1. Published literature on clinical signs & symptoms of T.b. rhodesiense HAT.
Buyst/1977 [18] Boatin/1986 [29] Wellde/1989 [35] Mbulamberi/1987 [36]
Number of patients 385 60 96 3152
Country Zambia Zambia Zambia Uganda
Disease stage of patients 2nd stage 2nd stage 2nd stage 1st stage
a
Male/female ratio N.A. 1.73 1.53 1.1
Chancre N.A. 5 15.6 19
Headache 66.2 73.3 95.8 95.8
Fever 31.2 71.7 36.4 96.8
Lymphadenopathy 80.5 N.A. 86.4 17.6
Itching or pruritus N.A. 35 53.1 N.A.
Oedema of face 30.1
b 21.7 3.1 27.5
Swelling of legs N.A. 43.3 25.3 N.A.
Joint pains N.A. 65 88.5 95
Day time sleep N.A. 63.3 70.8 26.8
c
Night time sleep N.A. 28.3 N.A. N.A.
Abnormal coordination N.A. N.A. 51 N.A.
Abnormal speech N.A. N.A. 38.5 N.A.
Mental confusion 17.4 N.A. N.A. N.A.
N.A: not applicable;
a98.7% of the patients were in the first stage and 1.3% of the patients in the second stage of the disease;
breported as oedema,
creported as somnolence.
doi:10.1371/journal.pntd.0000968.t001
Table 2. Demographic and diagnostic baseline characteristics.
Total (n=138) Tanzania (n=69) Uganda (n=69)
n% n% n%
Age (years), mean 6 SD 35619 38615 32622
Age (years), range (min.-max.) 6–85 9–70 6–85
Male female ratio 1.34 1.38 1.3
Age below 16 years 26 14 3 4 23 33
BMI
a (kg/m
2) - mean 6 SD 18.563.4 19.662.5 17.363.8
BMI,1 6 . 5 3 82 85 7 3 34 8
Malaria positive on admission 57 41 55 80 2 3
Trypanosomes in blood 131 95 68 99 63 91
Trypanosomes in CSF
b 1 1 4 8 35 58 05 98 6
WBC
c count in CSF
Median 70 134 20
Mean 6 SD 86682 135685 37640
0–20 cells/ul - no. (%) 35 25 0 35 51
21–100 cells/ul - no. (%) 52 38 23 33 29 42
.100 cells/ul - no. (%) 51 37 46 67 5 7
Patients excluded
d 14 N.A 3 N.A 11 N.A
Death upon arrival 6 N.A 3 N.A 3 N.A
Comatose upon arrival 8 N.A 0 N.A 8 N.A
N.A: not applicable;
aBody Mass Index,
bCSF: cerebrospinal fluid,
cWBC: white blood cell,
dexclusions due to other reasons (first stage infection, pregnancy) not shown.
doi:10.1371/journal.pntd.0000968.t002
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Student’s t test. Logistic regression was used to test differences
between groups of patients with different co-infections.
Results
The use of the abridged 10-day melarsoprol schedule for the
treatment of second stage T.b. rhodesiense HAT was highly
satisfactory (detailed safety and efficacy data to be published
separately). In this paper we describe the clinical presentation of
the disease in 138 second stage patients from Tanzania and
Uganda. The majority of patients were passively detected. Nine (9)
patients from Uganda (13%) were actively identified during a
survey of the National Agricultural Research Organisation
(NARO) in the HAT endemic region of the country. There was
no significant difference between actively and passively recruited
patients for the median WBC count in the CSF (actively detected:
median WBC=27, IQR=24; passively detected: median
WBC=19, IQR=43, p=0.067) and the median self-reported
duration of illness (actively detected: median=3 months, IQR=2,
passively detected: median=2 months, IQR=4, p=0.141). 14
patients (11 in Uganda and 3 in Tanzania) could not be examined
per protocol as they died or were in a comatose state upon arrival
at the study sites which led to an exclusion of those patients from
the IMPAMEL III trials.
By molecular analysis of blood samples, the presence of the SRA
gene [33] was demonstrated and confirmed T.b. rhodesiense
infection in all trial subjects [34].
Data on the demographic and diagnostic baseline characteristics
of the study population are shown in table 2. The proportion of
male (57.2%) and female (42.8%) patients was comparable. 18.8%
(26/138) trial participants were younger than 16 years whereof
88.5% (23/26) were enrolled in Uganda. There were no county-
specific differences for the presence of trypanosomes in blood and
CSF: 99% (68/69) of patients from Tanzania and 91% (63/69)
from Uganda had trypanosomes in blood (p=0.0524) and 70%
(55/69) and 86% (59/69) respectively had trypanosomes in the CSF
(p=0.3690). However, there was a significant difference for the
median WBC count in the CSF in Tanzania and Uganda (134 vs.
20 WBC/mm
3,p ,0.0001). Also, a body mass index (BMI) below
16.5 was more frequent in patients from Uganda (p,0.0001).
Clinical signs and symptoms reported at baseline and the level
of significance (95%) are summarized in table 3. Headache, fever,
general body pain and joint pains were common in both study
populations. Clinical suspicion for cardiac insufficiency was found
in both countries: 5.1% (7/138) of the patients had indication for
Table 3. Clinical signs and symptoms at baseline and treatment outcomes.
Total (n=138) Tanzania (n=69) Uganda (n=69) p-value
n% n% n%
Clinical signs & symptoms
Lymphadenopathy 27 19.6 7 10.1 20 29.0 0.0053
General body pain 132 95.7 69 100.0 63 91.3 0.0123
Headache 128 92.8 65 94.2 63 91.3 0.5114
Fever ($37.5uC) 37 26.8 20 29.0 17 24.6 0.5643
Fever (.38.5uC) 4 2.9 0 0.0 4 5.8 0.0424
Joint pains 129 93.5 67 97.1 62 89.9 0.0847
Diarrhea 9 6.5 1 1.4 8 11.6 0.0158
Pruritus 21 15.2 4 5.8 17 24.6 0.0003
Oedema 40 29.0 26 37.7 14 20.3 0.0244
Dyspnoe 10 7.2 1 1.4 9 13.0 0.0086
Cough 27 19.6 8 11.6 19 27.5 0.0183
Tremor 54 39.1 43 62.3 11 15.9 0.0001
Hepatomegaly 25 18.1 4 5.8 21 30.4 0.0002
Splenomegaly 51 37.0 11 15.9 40 58.0 0.0001
Walking difficulties 75 54.3 35 50.7 40 58.0 0.3928
Abnormal movements 36 26.1 31 44.9 5 7.2 ,0.0001
Sleeping disorder daytime 105 76.1 66 95.7 39 56.5 ,0.0001
Sleeping disorder night time 88 63.8 64 92.8 24 34.8 ,0.0001
Strange behaviour 25 18.1 15 21.7 10 14.5 0.2691
Disturbed appetite 120 87.0 60 87.0 60 87.0 1
Inactivity 100 72.5 57 82.6 43 62.3 0.0076
Speech impairment 16 11.6 6 8.7 10 14.5 0.2875
Aggressiveness 45 32.6 43 62.3 2 2.9 ,0.0001
Treatment outcomes
Death 15 10.1 7 10.1 8 11.6 0.7845
Cure (parasitological & clinical) 123 89.1 62 89.9 61 88.4 0.7845
doi:10.1371/journal.pntd.0000968.t003
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5.8% (8/138) for right heart insufficiency (combination of oedema
and hepatomegaly). Patients in Uganda had a more unspecific
presentation of the disease whereas specific signs and symptoms for
second stage HAT, namely sleeping disorders and aggressiveness
were more common in patients from Tanzania.
To look at changes of diagnostic markers and clinical signs and
symptoms over time we compared them in patients grouped by
self-reported duration of illness (see figure 1). In Tanzania and
Uganda 21.7% (15/69) and 36.2% (25/69) respectively were
diagnosed with HAT having signs and symptoms for one month or
less. 47.8% (33/69) of patients from Tanzania and 31.9% (22/69)
of patients from Uganda were diagnosed having signs and
symptoms of the disease between 1 and 3 months. Respective
percentages for diagnosis of HAT after feeling ill for more than 3
months were 30.4% (21/69) in Tanzania and 31.9% (22/69) in
Uganda. In both countries, the presence of trypanosomes in blood
and/or CSF and the WBC count in the CSF did not significantly
change over time. Also, there was no change over time for most of
the clinical signs and symptoms. However, we observed that
tremor (p=0.01), walking difficulties (p=0.040), sleeping disorders
at night (p=0.029), disturbed appetite (p=0.044) and aggressive-
ness (p,0.001) aggravated over time in all patients.
Per protocol, standard assessment of co-infections at baseline
included malaria and filariasis. 79.7% (55/69) of the patients from
Tanzania and 2.9% (2/69) from Uganda were malaria positive on
admission. None were found positive for filariasis. The HIV status
was determined on voluntary basis. In Tanzania, 94.2% (65/69) of
the patients tested their status and 24.6% (16/65) were found
positive. In Uganda, 31.9% (22/69) tested their status and 9.1%
(2/22) were found positive. We used the data from Tanzania to
study implications of malaria and HIV co-infections on the clinical
presentation and treatment outcomes of T.b. rhodesiense HAT. No
significant difference either in the clinical appearance or in
treatment outcomes for those patients was found. Details are
shown in table 4 and 5.
Discussion
Based on data from the IMPAMEL III trials we describe the
clinical presentation of second stage T.b. rhodesiense HAT in
Tanzania and Uganda and confirm a wide spectrum of clinical
presentation in these two geographically distinct areas in East
Africa. In both settings T.b. rhodesiense HAT followed the classical
disease pattern, but interestingly the neurological signs and
symptoms typical for HAT were seen in a relatively small
percentage of patients from Uganda. In patients from Tanzania,
however, they were the dominate clinical manifestation. This
correlated with the significantly higher reported CSF WBC counts
in patients from Tanzania.
Unspecific signs of the disease such as fever, headache, general
body pain and joint pains were reported in similar proportions in
both study populations. We observed fever ($37.5) in 29.7% (41/
138) of the trial subjects. In the literature, fever was reported in the
range of 31–71% in second stage patients from Zambia
[18,29,35]. In the two study populations we saw high fever
(.38.5) on admission only in Uganda (5.8%, 4/69) whereof 50%
were children. Fever seems to be more common in T.b. rhodesiense
than T.b. gambiense second stage patients in which fever was only
occasionally reported (16%) and high fever was mostly seen in
children [25]. In the two study populations, oedema was reported
in Uganda and Tanzania in 20.3% and in 37.7% of the patients,
Figure 1. Mean and 95% confidence interval for white blood cell (WBC) count in the central nervous system (CNS) by country and
reporting time.
doi:10.1371/journal.pntd.0000968.g001
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range of oedema in the literature (21.7–43.3%) [18,29,35,36].
The clinical aspects of T.b. gambiense HAT [21,25,26,37] have
been systematically studied and show that the hallmark of second
stage disease are neurological signs and symptoms [21,25].
Unfortunately, this has never been done for T.b. rhodesiense HAT
andhampers comparisons.However,published datareportsleeping
disorders during daytime hours with 63.3–70.5% of patients being
affected [29,35]. We observed sleeping disorders during daytime
hours in Uganda and Tanzania in 56.5% and in 95.7% of the
patients, respectively (p,0.0001). Similarly, sleeping disorders at
night time are reported in the literature in 28.3% of patients [29].
We observed it in 34.8% of the patients from Uganda and in 92.8%
of the patients from Tanzania (p,0.0001). Also other neurological
signs and symptoms were significantly more frequent in patients
from Tanzania; tremor (p=0.0001), abnormal movements
(p,0.0001), inactivity (p=0.0076) and aggressiveness (p,0.0001).
Clearly, the neurological signs and symptoms are more pronounced
in Tanzania than in Uganda, and when compared to the literature.
In Uganda, almost 50% of patients were in a poor nutritional
status (48% had BMI,16.5) as food security is very poor in this
part of the country. This most likely contributes to weakness and,
therefore, walking difficulties in the absence of neurological
symptoms. Malnutrition is associated with immunodeficiency
and higher susceptibility for a wide range of infections such as
tuberculosis [38,39] and pneumonia [40], as well as a poorer
response to treatment. Another potential consequence of malnu-
trition in Uganda is an increased number of patients admitted with
severe coma indicating a more rapid progression of the disease.
Yet, we assume that many HAT cases from T.b. rhodesiense endemic
areas in Tanzania die without ever having had contact with the
health system due to geographical isolation.
With regards to treatment outcomes, we did not see any
differences in the two study populations. In both countries all
patients were free of parasites at end of treatment. Also, there was
no apparent difference in parasite clearance rates. Time- and
treatment-dependant dynamics of CSF WBC counts in the two
study populations will be published separately.
Cardiovascular involvement is typical, but rarely of clinical
relevance in T.b. gambiense HAT [41,42]. We have limited
knowledge of the effects of cardiac involvement in T.b. rhodesiense
patients, but there is evidence that perimyocarditis seems to play
an important role in the clinical course and fatal outcomes [43,44].
We observed symptoms of cardiac failure such as oedema (swelling
of legs) in 29% of the patients. Hepatomegaly occurred in 18%,
dyspnoea in 7% and cough in 20% of the patients. However,
echocardiography or laboratory testing (i.e. brain natrium peptide)
could not be performed to confirm heart failure.
Table 4. Clinical signs and symptoms and treatment outcomes in malaria co-infected patients from Tanzania.
Total (n=69) Malaria negative (n=14) Malaria positive (n=55) p-value
n% n % n %
Clinical signs & symptoms
Lymphadenopathy 7 10.1 2 14.3 5 9.1 0.569
General Body Pain 69 100.0 14 100.0 55 100.0 N.A.
Headache 65 94.2 14 100.0 51 92.7 N.A.
Fever ($37.5uC) 20 29.0 3 21.4 17 30.9 0.488
Joint pains 67 97.1 14 100.0 53 96.4 N.A.
Diarrhea 1 1.5 0 0.0 1 1.8 N.A.
Pruritus 4 5.8 3 21.4 1 1.8 0.025
Oedema 26 37.7 7 50.0 19 34.6 0.291
Dyspnoe 1 1.5 0 0.0 1 1.8 N.A.
Cough 8 11.6 2 14.3 6 10.91 0.725
Tremor 43 62.3 12 85.7 31 56.4 0.058
Hepatomegaly 4 5.8 0 0.0 4 7.3 N.A.
Splenomegaly 11 15.9 3 21.4 8 14.6 0.533
Walking difficulties 35 50.7 8 57.1 27 49.1 0.591
Abnormal movements 31 44.9 6 42.9 25 45.5 0.862
Sleeping disorder daytime 66 95.7 11 78.6 55 100.0 0.046
Sleeping disorder night time 64 94.1 11 78.6 53 96.7 0.026
Strange behaviour 15 21.7 0 0.0 15 27.3 0.001
Disturbed appetite 60 87.0 9 64.3 51 92.7 0.010
Inactivity 57 82.6 12 85.7 45 81.8 0.732
Speech impairment 6 8.7 1 7.1 5 9.1 0.818
Aggressiveness 43 62.3 7 50.0 36 65.5 0.291
Treatment outcomes
Death 7 10.1 2 14.3 5 9.1 0.569
Cure (parasitological & clinical) 62 90.0 12 85.7 50 90.9 0.569
N.A: Malaria predicts presence/absence of sign and symptom perfectly.
doi:10.1371/journal.pntd.0000968.t004
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the patient population from Tanzania as the majority of the
patients were malaria-positive on admission (80%) and agreed to
voluntary testing of their HIV status (94.2%). Patients that were
malaria-positive on admission more often had pruritus (p=0.025),
sleeping disorders during day time hours (p=0.026) and disturbed
appetite (p=0.01). Also, they exhibited strange behaviour more
often (p=0.001). However, there is insufficient evidence for
profound differences in malaria-positive and malaria-negative
subjects, possibly due to asymptomatic carriers.
We identified one study that looked at T.b. rhodesiense and HIV co-
infections in 25 patients fromKenya. In termsof treatment outcomes
no conclusiveresultswereobtained[45].Ourresultsindicate thatthe
HIV status of the patient does not change the clinical presentation
and/or the treatment outcomes of T.b. rhodesiense HAT. For T.b.
gambiense HAT, there seems to be no association between HIV and
HAT infection rates [46,47] but evidence exists for a negative
association with treatment outcomes [47,48]. More research efforts
are needed to better understand the complex interactions of co-
infections, especially for neglected tropical diseases [49].
Our findings on the different clinical presentation of T.b.
rhodesiense HAT in the two study populations could be due to an
observation bias, bias in patient selection, or in comparing patients
at incongruous time points after infection. Bias due to co-infections
or differences in host and/or parasite genetics is also possible.
An observation bias can not be ruled out but is however less
likely as the IMPAMEL III program was conducted with a structured
case report form (CRF) and one monitoring person. We have seen
variability in signs and symptoms with clear definitions (e.g.
lymphadenopathy, abnormal movements or tremor) as well as
subjective definitions (e.g. insomnia, headache or inactivity). We
can not completely rule out a selection bias due to the exclusion of
moribund and unconscious patients in which baseline examination
per protocol was not possible. However, the number of excluded
patients was relatively small (,10%) and the two study
populations were similar in regards to self-reported duration of
illness. Even though unsuccessful, active case searches were
conducted in both countries which reduced a potential selection
bias. Central nervous system involvement in T.b. rhodesiense HAT
was previously reported within 3 weeks to 2 months of infection
[12]. One third of the study population already had clear
neurological signs and symptoms within one month of infection
which reflects the acuteness of T.b. rhodesiense infections. The WBC
count in the CSF as well as most of the clinical signs and symptoms
also developed quickly and did not significantly change over time.
Disease progression was noticeable by aggravation of tremor,
Table 5. Clinical signs and symptoms and treatment outcomes of HIV co-infected patients from Tanzania.
Total (n=65)
a HIV negative (n=49) HIV positive (n=16) p-value
n% n % n %
Clinical signs & symptoms
Lymphadenopathy 7 10.8 5 10.2 2 12.5 0.797
General body pain 65 100.0 49 100.0 16 100.0 N.A.
Headache 61 93.9 47 95.9 14 87.5 0.247
Fever ($37.5uC) 19 29.2 17 34.7 2 12.5 0.106
Joint pains 64 98.5 49 100.0 15 93.8 N.A.
Diarrhea 1 1.5 1 2.0 0 0 N.A.
Pruritus 2 3.1 2 4.1 0 0 N.A.
Oedema 23 35.6 17 34.7 6 37.5 0.839
Dyspnoe 65 100.0 49 100.0 16 100.0 N.A.
Cough 7 10.8 4 8.2 3 18.6 0.248
Tremor 40 61.5 31 63.3 9 56.3 0.617
Hepatomegaly 4 6.2 3 6.1 1 6.3 0.985
Splenomegaly 10 15.4 8 16.3 2 12.5 0.713
Walking difficulties 32 49.2 24 49.0 8 50.0 0.943
Abnormal movements 29 44.6 22 44.9 7 43.8 0.936
Sleeping disorder daytime 63 96.9 47 95.9 16 100.0 N.A.
Sleeping disorder night time 62 95.4 48 98.0 14 87.5 0.127
Strange behaviour 14 21.5 9 18.4 5 31.3 0.282
Disturbed appetite 57 87.7 44 89.8 13 81.3 0.373
Inactivity 53 81.5 40 81.6 13 81.3 0.973
Speech impairment 6 9.2 5 10.2 1 6.3 0.639
Aggressiveness 43 66.1 34 69.4 9 56.3 0.338
Treatment outcomes
Death 7 10.8 6 12.2 1 6.3 0.510
Cure (clinical & parasitological) 58 84.1 43 87.8 15 93.8 0.510
N.A: HIV predicts presence/absence of sign and symptom perfectly,
afour (4) patients from Tanzania did not test their HIV status.
doi:10.1371/journal.pntd.0000968.t005
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appetite and aggressiveness over time, in both study populations.
Based on the results shown we rule out a bias of our findings due
to co-infections. Previous infections with trypanosomes and/or host
genetics might be determinantsforthedifferent clinicalpresentation
of the disease in Tanzania and Uganda. There are speculations that
apathogenic forms of the disease could influence immune responses
to pathogenic infections [50,51] supported by the fact that HAT is
more acute in white than in the black populations [52,53]. But we
also see a high variability in disease severity among African
populations [17,18], a fact that has been related to the descent of
people: people of Nilotic descent, who migrated into the East
African region from tsetse-free areas during the past 2,000 years
may have less tolerance than people of Bantu descent, whose
ancestors have been exposed to human trypanosomes for several
thousand years [18]. Our findings do not align with this theory as in
Tanzania, the majority of the population is of Bantu origin and in
Uganda the majority of the population is of Nilotic origin. Different
parasite genotypes could be responsible for the observed spectrum
of disease severity, a hypothesis has already beenraised 60 years ago
[16,17,54]. Recent findings on the phylogenetic relationship
between different T.b. rhodesiense strains showed that the high
variability of the T.b. rhodesiense genome is attributed to multiple and
independent evolutions from T.b. brucei [55]. Our data show a clear
difference in the clinical presentation of T.b. rhodesiense HAT in
Tanzania and Uganda but a detailed assessment of host and
parasite genotypes was beyond the scope of this paper.
T.b. rhodesiense HAT is a highly neglected disease and tools for
disease control are very limited. There are no sensitive diagnostics
at hand and melarsoprol, the only available drug to treat second
stage disease, is toxic. An early identification of the disease is vital
to prevent late onset of treatment. However, most of the patients
are first treated for other conditions such as malaria and
pneumonia. A low degree of disease awareness among health
personnel is common and aggravated by the low prevalence and
the focal distribution of HAT. A detailed understanding of the
clinical presentation and regional characteristics of T.b. rhodesiense
HAT is important and can support decision making and
differential diagnosis at health facility level.
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